Title : Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.

Pub. Date : 2017 Jan 3

PMID : 27880942






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT. Vemurafenib MET proto-oncogene, receptor tyrosine kinase Homo sapiens